AST-008

AST-008 is an experimental small molecule therapeutic being developed by Astrocyte Pharmaceuticals for the treatment of pain and migraine. It is part of a platform of astrocyte-targeted therapies designed to enhance the natural neuroprotective and metabolic support functions of astrocytes in the central nervous system. While specific target details for AST-008 are often undisclosed in early pipeline stages, the company's core technology focuses on the selective activation of adenosine A1 and A3 receptors to promote brain health and recovery. AST-008 is specifically optimized for chronic indications, distinguishing it from the company's lead acute-care candidate, AST-004.